Abbott Laboratories (ABT)
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Why Abbott (ABT) Outpaced the Stock Market Today
Abbott (ABT) closed at $114.63 in the latest trading session, marking a +1.12% move from the prior day.
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Cramer's Stop Trading: Abbott Labs
CNBC's Jim Cramer explains why he is keeping an eye on shares of Abbott Labs.
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry.
Abbott (ABT) Outperforms Broader Market: What You Need to Know
Abbott (ABT) concluded the recent trading session at $113.64, signifying a +0.07% move from its prior day's close.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott, Reckitt face trial over premature baby formula amid alarm from doctors
A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories' top line was somewhat inconsistent in recent years due to swings in its COVID-related revenues. Johnson & Johnson has been restructuring, spinning off its consumer health segment and bolstering its medical device segment by acquiring Abiomed.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
